← HCA Healthcare, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $2.9b
$2.2b -23.32%
$3.8b +70.89%
$3.5b -7.45%
$3.8b +7.10%
$7.0b +85.30%
$5.6b -18.88%
$5.2b -7.11%
$5.8b +9.88%
$6.8b +17.78%
—
Net Income (Loss) Attributable to Noncontrolling Interest $542.0m $527.0m $602.0m $640.0m $633.0m $765.0m $1.2b $849.0m $897.0m $998.0m —
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $3.4b $2.7b $4.4b $4.1b $4.4b $7.7b $6.8b $6.1b $6.7b $7.8b —
Amortization of Debt Issuance Costs $34.0m $31.0m $31.0m $30.0m $30.0m $27.0m $29.0m $35.0m $35.0m $44.0m —
Amortization of Intangible Assets — — — — — $25.0m $44.0m $20.0m $16.0m $12.0m —
Depreciation $1.9b $2.1b $2.3b $2.6b $2.7b $2.8b $2.9b $3.1b $3.3b $3.5b $3.7b
Depreciation, Depletion and Amortization $2.0b $2.1b $2.3b $2.6b $2.7b $2.9b $3.0b $3.1b $3.3b $3.5b $3.7b
Share-based Payment Arrangement, Noncash Expense $251.0m $270.0m $268.0m $347.0m $362.0m $440.0m $341.0m $262.0m $360.0m $401.0m $375.0m
Share-based compensation $251.0m $270.0m $268.0m $347.0m $362.0m $440.0m $341.0m $262.0m $360.0m $401.0m $375.0m
Goodwill, Impairment Loss $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 —
Income (Loss) from Equity Method Investments $54.0m $45.0m $29.0m $43.0m $54.0m $113.0m $45.0m $22.0m $23.0m $78.0m —
Changes in operating assets and liabilities:
Accounts receivable ($3.2b) ($4.6b) ($423.0m) ($326.0m) $327.0m ($962.0m) ($797.0m) ($935.0m) ($799.0m) ($94.0m) ($1.8b)
Increase (Decrease) in Accounts Receivable $3.2b $4.6b $423.0m $326.0m ($327.0m) $962.0m $797.0m $935.0m $799.0m $94.0m ($1.8b)
Inventories and other assets ($112.0m) ($69.0m) ($242.0m) ($158.0m) ($304.0m) ($540.0m) ($59.0m) ($126.0m) $334.0m ($154.0m) —
Accounts payable and accrued expenses $144.0m $374.0m $698.0m $396.0m $1.3b $999.0m ($296.0m) $604.0m $359.0m $666.0m —
Other ($98.0m) ($45.0m) ($248.0m) ($142.0m) ($205.0m) ($284.0m) ($212.0m) ($246.0m) ($277.0m) ($185.0m) —
Net Cash Provided by (Used in) Operating Activities $5.7b
$5.4b -4.02%
$6.8b +24.60%
$7.6b +12.44%
$9.2b +21.44%
$9.0b -2.96%
$8.5b -4.88%
$9.4b +10.67%
$10.5b +11.48%
$12.6b +20.18%
$11.1b -11.97%
Cash flows from investing activities:
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property $23.0m $8.0m $428.0m $18.0m ($7.0m) $1.6b $1.3b ($5.0m) $14.0m $37.0m ($48.0m)
Payments to Acquire Property, Plant, and Equipment $2.8b $3.0b $3.6b $4.2b $2.8b $3.6b $4.4b $4.7b $4.9b $4.9b ($5.1b)
Change in investments $64.0m ($73.0m) $57.0m $25.0m ($20.0m) ($117.0m) $14.0m ($112.0m) ($115.0m) $72.0m —
Payments for (Proceeds from) Other Investing Activities ($6.0m) $4.0m ($60.0m) ($34.0m) $38.0m $4.0m $21.0m $19.0m $5.0m ($12.0m) —
Net Cash Provided by (Used in) Investing Activities ($3.2b) ($4.3b) ($3.9b) ($5.7b) ($3.4b) ($2.6b) ($3.4b) ($5.3b) ($4.9b) ($5.0b) ($5.5b)
Cash flows from financing activities:
Gain (Loss) on Extinguishment of Debt ($4.0m) ($39.0m) ($9.0m) ($211.0m) ($295.0m) ($12.0m) ($78.0m) $0 $0 — —
Issuances of long-term debt $5.4b $1.5b $2.0b $6.5b $2.7b $4.3b $6.0b $3.2b $7.5b $8.5b —
Net change in short-term borrowings and revolving credit facilities ($110.0m) $760.0m ($640.0m) ($560.0m) ($2.5b) $2.8b $120.0m ($1.0b) ($1.9b) $2.2b —
Payment of debt issuance costs ($40.0m) ($26.0m) ($25.0m) ($73.0m) ($35.0m) ($38.0m) ($53.0m) ($31.0m) ($67.0m) ($79.0m) —
Proceeds from Issuance of Long-term Debt $5.4b $1.5b $2.0b $6.5b $2.7b $4.3b $6.0b $3.2b $7.5b $8.5b $6.2b
Repayment of long-term debt ($4.5b) ($753.0m) ($1.7b) ($5.3b) ($3.4b) ($3.9b) ($2.8b) ($909.0m) ($2.4b) ($7.4b) —
Repayments of Long-term Debt $4.5b $753.0m $1.7b $5.3b $3.4b $3.9b $2.8b $909.0m $2.4b $7.4b ($4.3b)
Payments for Repurchase of Common Stock $2.8b $2.1b $1.5b $1.0b $441.0m $8.2b $7.0b $3.8b $6.0b $10.1b —
Repurchase of common stock ($2.8b) ($2.1b) ($1.5b) ($1.0b) ($441.0m) ($8.2b) ($7.0b) ($3.8b) ($6.0b) ($10.1b) —
Dividends paid — — $487 $550 $153 $624 $653 $661 $690 $679 ($682.0m)
Payment of dividends — $0 ($487.0m) ($550.0m) ($153.0m) ($624.0m) ($653.0m) ($661.0m) ($690.0m) ($679.0m) —
Net Cash Provided by (Used in) Financing Activities ($2.5b)
($1.1b) +57.70%
($3.1b) -189.82%
($1.8b) +42.41%
($4.7b) -164.09%
($6.7b) -42.29%
($5.7b) +15.01%
($4.1b) +27.62%
($4.6b) -11.92%
($8.6b) -86.60%
($5.5b) +35.67%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — $0 ($230.0m) $119.0m $1.2b ($342.0m) ($543.0m) $27.0m $998.0m ($893.0m) $1.0b
Cash and cash equivalents at beginning of period $741.0m $646.0m $502.0m $621.0m $1.8b $1.5b $908.0m $935.0m $1.9b $1.0b —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — $502.0m $621.0m $1.8b $1.5b $908.0m $935.0m $1.9b $1.0b $1.0b
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $0 ($15.0m) $8.0m $10.0m ($3.0m) ($20.0m) $7.0m ($1.0m) $9.0m ($6.0m)
Effect of exchange rate changes on cash and cash equivalents — $0 ($15.0m) $8.0m $10.0m ($3.0m) ($20.0m) $7.0m ($1.0m) $9.0m ($6.0m)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Acquisition of hospitals and health care entities ($576.0m) ($1.2b) ($1.3b) ($1.7b) ($568.0m) ($1.1b) ($224.0m) ($635.0m) ($266.0m) ($397.0m) —
Additional Financial Items
Change in cash and cash equivalents ($95.0m) $86.0m ($230.0m) $119.0m $1.2b ($342.0m) ($543.0m) $27.0m $998.0m ($893.0m) —
Distributions to noncontrolling interests ($434.0m) ($448.0m) ($441.0m) ($542.0m) ($626.0m) ($749.0m) ($1.0b) ($640.0m) ($711.0m) ($827.0m) —
Gain (Loss) Related to Litigation Settlement $246.0m — — — — — — — — — —
General and Administrative Expense $373.0m $373.0m $344.0m $370.0m $416.0m $400.0m $378.0m $315.0m $421.0m $548.0m —
Income Tax Expense (Benefit) $1.4b $1.6b $946.0m $1.1b $1.0b $2.1b $1.7b $1.6b $1.9b $2.0b —
Income Taxes Paid, Net $1.3b $1.2b $872.0m $849.0m $1.0b $2.2b $1.2b $1.4b $1.8b $1.7b —
Income taxes $123.0m $433.0m $74.0m $250.0m $41.0m ($70.0m) $571.0m $229.0m $22.0m $310.0m —
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.7b $1.7b $1.7b $1.9b $1.6b $1.5b $1.7b $1.9b $1.9b $2.2b —
Interest payments $1.7b $1.7b $1.7b $1.9b $1.6b $1.5b $1.7b $1.9b $1.9b $2.2b —
Losses (gains) on sales of facilities ($23.0m) ($8.0m) ($428.0m) ($18.0m) $7.0m ($1.6b) ($1.3b) $5.0m ($14.0m) ($37.0m) —
Operating Lease, Expense — — — $389.0m $447.0m $478.0m $484.0m — — — —
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax ($69.0m) ($13.0m) $8.0m $14.0m ($19.0m) — — — — — —
Revenue from Contract with Customer, Including Assessed Tax — — $46.7b $51.3b $51.5b — — — — — —
Sales of hospitals and health care entities $26.0m $25.0m $808.0m $61.0m $68.0m $2.2b $1.2b $193.0m $328.0m $269.0m —
Supplemental disclosure of cash flow information:

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.